Please assess the completion status of the following clinical trial:

Trial Title: A Research Study to Assess if CC-930 is Safe in Treating Subjects With Discoid Lupus Erythematosus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female with clinical diagnosis of Discoid Lupus Erythematosus (DLE) aged 18 to 64 years~2. Good health as assessed by Investigator~3. DLE for at least 16 weeks prior to screening and consistent histological findings.~4. Considered a candidate for systemic therapy. May be naïve to systemic therapy or experiencing incomplete or refractory disease on systemic therapy.~5. Cutaneous Lupus Area and Severity Index (CLASI) activity score of at least 10, as determined by investigator.~6. Subjects using hydroxychloroquine, chloroquine, or quinacrine must have documented ophthalmologic exam within 24 weeks of baseline visit.~7. Must meet laboratory criteria for white blood cells, absolute neutrophils, platelets, serum creatinine, aspartate aminotransferase (AST), alanine aminotransferase (ALT), bilirubin and hemoglobin.~8. Subjects, male and female, must agree to strict pregnancy prevention and testing requirements.~Exclusion Criteria:~1. Significant illnesses as determined by physician.~2. History of significant cardiac conditions or interventions within prior 6 months including abnormal electrocardiogram (ECG) findings.~3. Systolic blood pressure \< 95 or \> 150 mm Hg~4. Diastolic blood pressure \> 90 mm Hg.~5. Pregnancy or breast feeding.~6. Other dermatological conditions that would interfere with CLASI Activity Score assessments.~7. History of or active; malignancy, human immunodeficiency virus (HIV), tuberculosis infection, other mycobacterial infection, congenital or acquired immunodeficiency, Hepatitis B and C.~8. Clinically significant abnormality on chest X-ray.~9. Participation in multiple CC-930 cohorts.~10. History of thrombolytic event.~11. Positive tests for lupus anticoagulant, anti-cardiolipin antibodies, antibodies to beta-2 glycoprotein 1 or phosphatidylserine at screening.~12. Positive antineutrophilic cytoplasmic antibody (ANCA) at screening.~13. Diagnosis of SLE.~14. Presence or history of medically significant Systemic Lupus Erythematosis (SLE) or Lupus Erythematosis (LE) comorbidities.~15. History of seizures, chorea or psychosis.~16. Presence or history of persistent proteinuria or urinary cellular casts.~17. Prohibited prior or concomitant medications.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): 25 mg daily for 4 weeks (8 active/2 control)
- Cohort 2 (Type: EXPERIMENTAL): 50 mg once daily for 4 weeks (8 active/2 control)
- Cohort 3 (Type: EXPERIMENTAL): 100 mg daily for 6 weeks (8 active/2 control)
- Cohort 4 (Type: EXPERIMENTAL): 100 mg twice daily for 6 weeks (8 active/2 control)

Based on this trial design, predict the completion outcome and termination type (if applicable).